VGX-1027

Research use only, not for human use.

VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.

VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.(In Vitro):VGX-1027 (37.5, 75, 150, 300 μM; for 24 h) does not affect the viability of tumor cells，including the three malignant rodent cell lines (mouse fibrosarcoma L929, rat astrocytoma C6, and mouse melanoma B16) and the four human cell lines (adenocarcinoma HeLa, breast carcinoma BT20, colon carcinoma LS174, and glioblastoma U251).(In Vivo):VGX-1027 (10, 20 mg/kg of i.p. for 12 day or 100 mg/kg of p.o. for 11 day) successfully counteractes the development of destructive insulitis and hyperglycemia.VGX-1027 (25 mg/kg; ip; single dose) counteracts the uveitis-inducing effect of LPS in eight-week-old male Lewis rats (180-220 g).

VGX-1027 (37.5, 75, 150, 300 μM; for 24 h) does not affect the viability of tumor cells，including the three malignant rodent cell lines (mouse fibrosarcoma L929, rat astrocytoma C6, and mouse melanoma B16) and the four human cell lines (adenocarcinoma HeLa, breast carcinoma BT20, colon carcinoma LS174, and glioblastoma U251).

VGX-1027 (10, 20 mg/kg of i.p. for 12 day or 100 mg/kg of p.o. for 11 day) successfully counteractes the development of destructive insulitis and hyperglycemia. VGX-1027 (25?mg/kg; ip; single dose) counteracts the uveitis-inducing effect of LPS in eight-week-old male Lewis rats (180-220?g). Animal Model:Adult male mice, at 6 to 8 weeks of age with 25 to 30 g Dosage:10, 20 mg/kg for i.p. or 100 mg/kg for p.o.Administration:IP daily for 12 consecutive day or PO daily for 11 consecutive day Result:Successfully counteracted the development of destructive insulitis and hyperglycemia to the mice made diabetic with multiple low doses of Streptozotocin.

VGX-1027

Apoptosis

IL Receptor

IL-10| IL-1β| TNF-α

Inflammation/Immunology

——

6501-72-0

205.21

C11H11NO3

>98% (HPLC)

Ethanol: 41 mg/mL (199.79 mM); DMSO: 41 mg/mL (199.79 mM)

O=C(O)CC1CC(C2=CC=CC=C2)=NO1

2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid

(-20℃)

With Ice Pack

≥ 2 years